CTXR Citius Pharmaceuticals, Inc.
$0.76
Citius Pharmaceuticals, Inc. (CTXR) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $0.25 per share.
Citius Pharmaceuticals, Inc. Beat Consensus Estimates
Friday, August 14, 2026 · 4:30 PM ET
Earnings Date
4th Quarter, Sep 2026
Nov 13
Friday · 4:30 PM ET
Earnings Whisper
-
vs ($0.25)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$0.62
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies.
Sector
Healthcare
Industry
Drug Manufacturers/Other